BC Week In Review | Jan 18, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
BC Extra | Jan 17, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
BC Week In Review | May 12, 2017
Company News

Clinigen launches European managed access program for Beleodaq from Onxeo

Clinigen Group plc (LSE:CLIN) launched a managed access program in Europe for Beleodaq belinostat from Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO) to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). Under the program, Beleodaq will be available...
BC Week In Review | Feb 29, 2016
Company News

Onxeo, University of Navarra deal

The university will conduct preclinical trials evaluating Onxeo’s Beleodaq belinostat and Livatag doxorubicin in combination with immuno-oncology compounds, including PD-1 and CTLA-4 (CD152) inhibitors in models of hepatocellular carcinoma (HCC). Results are expected next half....
BC Week In Review | Feb 1, 2016
Company News

Spectrum Pharmaceuticals, Servier deal

Spectrum granted Servier’s Servier Canada Inc. affiliate exclusive, Canadian rights to develop and commercialize four cancer drugs. The deal covers Zevalin ibritumomab for follicular B cell non-Hodgkin’s lymphoma (NHL); Fotolyn pralatrexate and Beleodaq belinostat for...
BC Week In Review | Dec 14, 2015
Clinical News

Beleodaq belinostat: Phase I data

The open-label, dose-escalation, U.S. Phase I BelCHOP trial in 18 evaluable patients with PTCL showed that IV belinostat plus CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) as first-line treatment led to an ORR of 89%,...
BC Week In Review | Jun 22, 2015
Clinical News

Belinostat: Additional Phase I/II data

Additional data from 20 patients in the Phase II portion of the open-label Phase I/II PXD101-CLN-14 trial showed that belinostat plus doxorubicin led to an ORR of 13%, including 1 complete response at cycle 2...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
BC Extra | Nov 19, 2014
Financial News

Onxeo proposes EUR 35.4M rights offering

Orphan cancer company Onxeo S.A. (Euronext:ONXEO) proposed to raise EUR 35.4 million ($44.1 million) in a rights offering underwritten by Natixis and Oddo & Cie. The company plans to issue 7.9 million shares at EUR...
BC Innovations | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer; ovarian cancer Histone deacetylase (HDAC) In vitro and mouse studies suggest thioacetate-lactam carboxamide analog-based pan-HDAC inhibitors could help treat colorectal or ovarian cancer....
Items per page:
1 - 10 of 203